CannaPacific is an Australian domiciled biotechnology company with an end to end focus on the production of novel cannabis varieties to support the development of cannabinoid-based medicines for patients with unmet medical needs. By combining advanced molecular breeding technology with our affiliate e3D Pharma’s traditional approach to drug development we seek to build a global therapeutic offering.
Our strategy is to attain a world-leading position in the production of medical cannabis varieties. We will achieve this through the research, development and advanced plant science services to the medicinal cannabis industry while supporting the development of authorised pharmaceuticals through our affiliate e3D Pharma.
CannaPacific manufactures its medicinal cannabis and pharmaceutical products to meet the stringent cGMP requirements of the US FDA, EMA, Australian TGA and other global regulatory authorities. CannaPacific controls all facets of plant-based cannabinoid production, product development, manufacturing and commercial distribution.
CannaPacific is licenced by the Australian Government to cultivate and research medicinal cannabis products via its 18ha manufacturing site near Byron Bay, NSW. The site performs molecular and genomic plant breeding R&D and cultivates unique low cost, compliant cannabis strains for the production of novel cannabinoid-based medicines. The site also provides contract growing and cultivation services for the global medicinal cannabis industry.